Gabapentin Tablet, Film Coated
Product Images NDC 71205-160

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor adjustment for female patients (0.85). This text panel displays a pharmacokinetic equation relevant to drug dosing considerations.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of the active ingredient gabapentin, showing its cyclohexane ring with attached amine and carboxyl groups.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph illustrating the mean pain score over 8 weeks comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks from baseline to 8 weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain score ranging from 0 to 10. The graph shows pain scores decreasing over time for gabapentin while remaining relatively stable for placebo.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain score over 7 weeks for placebo and gabapentin at 1800 mg/day and 2400 mg/day dosages. The x-axis indicates weeks, with a 3-week dose titration period followed by a 4-week fixed dose period. Mean pain scores decrease more for gabapentin groups compared to placebo over time.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing response rates from two studies. The y-axis represents percentage responders from 0% to 100%. Study 1 compares placebo (12%) to Gabapentin 3600 mg (29%). Study 2 compares placebo (14%) to Gabapentin 1800 mg (32%) and 2400 mg (34%). Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing the percentage difference in response at daily Gabapentin doses of approximately 600 mg, 900 mg, and 1800 mg across three studies (Study A, Study B, Study C). The vertical axis shows the difference percentage, while the horizontal axis shows daily dose in milligrams, with individual data points for each study.*

FDA Label Image

71205-160-60 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 07)

Gabapentin 800 mg film-coated tablets carton label by Proficient Rx LP. Contains 60 oral tablets. Label includes dosing and safety instructions, manufacture details from Strides Shasun Limited in India, and NDC 71205-160-60. The tablets are described as white to off-white, oval, with deep scoring and debossing on one side. Includes QR codes and standard regulatory information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.